This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Skyrizi (risankizumab)
General Description:
Skyrizi (risankizumab) is a humanized monoclonal antibody developed for the treatment of adult patients with moderate-to-severe plaque psoriasis and active psoriatic arthritis.
It works by selectively targeting and inhibiting the interleukin-23 (IL-23) cytokine, which plays a key role in inflammation and the overproduction of skin cells associated with psoriasis. By blocking IL-23, Skyrizi helps reduce plaques, scaling, redness, and joint inflammation, improving skin clearance and overall quality of life for patients.
Disease Indications:
• Plaque Psoriasis
• Psoriatic Arthritis (PsA)
Manufacturer:
AbbVie Ltd
Usage:
Subcutaneous Injection
Medicine Approved by:
• European Medicines Agency (EMA)
• Food and Drug Administration (FDA)
• Therapeutic Goods Administration (TGA)
Package:
• Pre-filled syringe: 150 mg/mL
• 1 vial × 600 mg
• Pre-filled pen × 150 mg
• Solution for injection in cartridge × 360 mg
Shipping:
Cold Chain Shipping
Skyrizi contains temperature-sensitive biological ingredients that must be protected from heat, light, and mishandling. To maintain its stability and therapeutic effectiveness, it is shipped under cold chain delivery conditions using specialized medical couriers equipped with temperature-regulated packaging and vehicles.
Although cold chain shipping may involve higher costs compared to standard delivery, it ensures that Skyrizi remains safe, stable, and effective for patient administration.
How to Access Skyrizi (risankizumab) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Skyrizi (risankizumab) is not yet approved or commercially available in India, MitoGENE can assist patients and healthcare providers in obtaining it legally through the Named Patient Program (NPP).
Here’s how the process works:
